Physician profile
Janna Wayne
NPI 1730675471
$7,022.80
in general payments reported to CMS, 2019-2025
23 companies · $2,135 in 2025
The $2,135 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $976 · 2022: $1,475 · 2023: $1,190 · 2024: $1,247 · 2025: $2,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,460 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,459.86 |
| Education | $112.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,268.43 | 2022-2025 | |
| Optinose US, INC. | $756.39 | 2021-2025 | |
| Genzyme Corporation | $722.03 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $705.18 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $682.68 | 2022-2025 | Nucala |
| Pfizer INC. | $594.10 | 2023-2025 | |
| Acclarent, INC | $436.03 | 2021-2023 | Relieva Spinplus |
| Aerin Medical INC. | $415.72 | 2025 | |
| Phathom Pharmaceuticals, INC. | $267.01 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $236.32 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $192.23 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $160.74 | 2021-2025 | Tezspire |
| Amgen INC. | $133.17 | 2021-2025 | Tezspire |
| Axsome Therapeutics, INC. | $124.56 | 2025 | Symbravo |
| Stryker Corporation | $92.03 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $54.88 | 2023 | Propel |
| Phadia US INC. | $52.19 | 2021-2024 | Immunocap |
| Vertex Pharmaceuticals Incorporated | $31.22 | 2025 | |
| Lilly USA, LLC | $27.80 | 2022 | |
| Intersect Ent, INC. | $27.71 | 2021 | |
| Kaleo, INC. | $14.56 | 2023 | Auvi-Q |
| Pacira Pharmaceuticals Incorporated | $14.22 | 2023 | Zilretta, Exparel, Iovera |
| Kowa Pharmaceuticals America, INC. | $13.60 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janna Wayne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.